Skip to main content
. Author manuscript; available in PMC: 2023 Apr 1.
Published in final edited form as: Eur J Heart Fail. 2022 Mar 14;24(4):685–693. doi: 10.1002/ejhf.2463

Figure 3.

Figure 3

Improved event-free survival in LMNA cardiomyopathy patients with response to cardiac resynchronization therapy (CRT). The primary endpoint was death, transplantation or left ventricular assist device implantation. CRT responder defined as improvement in left ventricular ejection fraction ≥5% after 6 months. *Number at risk.